The other drugs — Jardiance and Taltz — generated double-digit sales growth, while Trulicity slumped 31% year over year. Eli Lilly increased its full-year outlook for the second time this year.

Trulicity (dulaglutide) grew more than expected to reach $1.2 billion in the period, a rise of 31% that came despite pricing pressure in the US and competition from Novo Nordisk’s rival once ...

StudyFinds' Dr. Faith Coleman looks at the common mistakes patients make using GLP-1 agonists like Ozempic and Wegovy.

Consequently, when attempting to climb the career ladder into a new leadership or management role, it can be very hard to pinpoint what your strengths are and sell them effectively to your ...

In this article, we will discuss: 12 Best Growth Stocks To Buy According To Hedge Funds.

"There is a clear association between the use of GLPs and increased risks of food retention during upper endoscopy," Mathur ...

The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist Trulicity (dulaglutide), which is competing head-to-head with Ozempic in the market ...

Ozempic and similar drugs are often effective because they produce feelings of satisfaction, in line with the NBC theory of ...

Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs.

The company also saw a 31% decline in worldwide Trulicity revenue in Q2 ... This complex interplay of strengths, weaknesses, opportunities, and threats will shape Eli Lilly's financial stability ...

Listing Wilson on her own as a strength may seem like a joke, but she's the most dominant player in women's basketball in the midst of her best season. How often do you see a center finish near ...

We recently compiled a list of the 8 Best Momentum Stocks To Invest In Right Now. In this article, we are going to take a ...